Nintedanib Reduces Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Results of the SENSCIS Trial

Autor:	O. Distler, K.B. Highland, M. Gahlemann, A. Azuma, A. Fischer, M.D. Mayes, G. Raghu, W. Sauter, M. Girard, M. Alves, E. Clerisme-Beaty, S. Stowasser, K. Tetzlaff, M. Kuwana, T.M. Maher, null for the SENSCIS trial investigators
Rok vydání:	2019
Předmět:	medicine.medical_specialty chemistry.chemical_compound chemistry business.industry Internal medicine medicine Interstitial lung disease Nintedanib In patient business medicine.disease Gastroenterology Lung function
Zdroj:	B17. ADVANCES IN ILD THERAPY.
DOI:	10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7360
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::78bb57bba9070e496bc4df3b16e22090 https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7360 Zobrazit plný text záznamu